Skip to content
‹ Back to IndustriesHealthcare

X-Nav Technologies Recaps AAOMS 2022

The 104th annual meeting of the American Association of Oral and Maxillofacial Surgeons (AAOMS) took place in New Orleans on September 12-15, 2022, and brought together oral surgeons from around the globe. The AAOMS 2022 conference centered around the theme “Volunteerism: Individuals United in Service,” with many courses and educational sessions allowing attendees…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from X-Nav on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The 104th annual meeting of the American Association of Oral and Maxillofacial Surgeons (AAOMS) took place in New Orleans on September 12-15, 2022, and brought together oral surgeons from around the globe. The AAOMS 2022 conference centered around the theme “Volunteerism: Individuals United in Service,” with many courses and educational sessions allowing attendees to earn up to 32 C.E. credits, doubling the typical number from past years​​. The exhibit hall teemed with over 200 exhibitors, showcasing cutting-edge oral and maxillofacial surgery products, services, and technologies. One of these exhibitors was X-Nav Technologies, marking its tenth anniversary at the event​​.

What makes this milestone for X-Nav Technologies particularly significant? How have they transformed the landscape of oral and maxillofacial surgery over the past decade, and what can we expect from them in the years to come?

In this episode of On-Point by X-Nav Technologies, co-founder and VP of Sales Chris Scharff recapped the AAOMS 2022 meeting and discussed the strides X-Nav has made over the last decade. Highlights from the conference include:

  • X-Nav’s celebration of their tenth anniversary and their presence at the AAOMS meeting, where they engaged with existing customers and met with potential new ones
  • Their X-Guide navigation system, now installed in over 45 countries and has facilitated over 2,000 implants, demonstrating its global impact and staying power in the industry
  • The exceptional accuracy of the X-Guide system

Apart from being the co-founder and V.P. of Sales at X-Nav Technologies, Chris Scharff has an extensive dental technology background. His leadership and sales acumen have driven the company’s growth and innovation over the past ten years. As a stalwart advocate for emerging technologies in the field, Chris continues to push the boundaries of what’s possible in oral and maxillofacial surgery, ensuring X-Nav remains at the forefront of industry advancements.

Video TranscriptExpand ↓

Very excited to be at the oral surgery meeting to see our existing customers as well as to meet new doctors and hopefully welcome them to our XNA family. This actually marks our ten year anniversary. So if someone's looking at the x guide, it's a great time to come, not only with us being in and boasting some great global milestones. Like for example, we have been through regulatory and are installed in over forty five countries now. We also have navigated over two thousand implants. So the technology is here to stay and it's a great time to come, but not only that, it's a great time to come when you talk about innovation. Lots more innovation from X NAV. We're so excited to show you this throughout the years and many more things to come. But this is what we are showing now at the oral surgery meeting and happy to have you here. The good thing about this system is that so accurate. It eliminates all the inaccuracies within two degrees of freedom rather than eight degrees of error. So it's just It's the accuracy and the patient treatment is so much better.

X-Nav

Part of this channel

X-Nav

Digital dental navigation that improves accuracy and patient outcomes.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

  • 01Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.
  • 02In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.
  • 03Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Nov 22, 2026

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512